Airway mucus was collected from healthy and chronic bronchitic subjects. The chronic bronchitic sputum was separated into gel and sol phase by centrifugation and mucins were isolated using isopycnic density-gradient centrifugation in CsCl. The presence of the MUC5AC and MUC2 mucins was investigated with antisera raised against synthetic peptides with sequences from the respective apoproteins. The gel and sol phase of chronic bronchitic sputum as well as healthy respiratory secretions were shown to contain MUC5AC whereas the MUC2 mucin could not be detected. Rate-zonal centrifugation showed that the MUC5AC mucin was large, polydisperse in size and that reduction yielded subunits. Ion-exchange HPLC revealed the presence of two subunit populations in all secretions, the MUC5AC subunits always being the more acidic. MUC5AC is thus the first large, subunit-based, gel-forming respiratory mucin identified and this glycoprotein is biochemically distinct from at least one other population of large, gel-forming mucins also composed of subunits but lacking a genetic identity.

The "insoluble" glycoprotein complex was isolated from human colonic tissue and mucin subunits were prepared following reduction. Antibodies raised against peptide sequences within MUC2 revealed that virtually all of this mucin occurs in the insoluble glycoprotein complex. In addition, reduction released a 120-kDa Cterminal MUC2 fragment, showing that proteolytic cleavage in this domain may occur and leave the fragment attached to the complex via disulfide bonds. The variable number tandem repeat region and the irregular repeat domain were isolated after trypsin digestion and shown to have molecular weights of 930,000 and 180,000, respectively, suggesting a molecular weight for the entire MUC2 monomer of approximately 1.5 million. Gel chromatography and agarose gel electrophoresis revealed several populations of MUC2 subunits, and analytical ultracentrifugation showed that these have molecular weights on the order of 2 million, 4 million, and 5 million, corresponding to monomers, dimers, and trimers, respectively. Agarose gel electrophoresis of subunits from individuals expressing both a "long" and a "short" MUC2 allele revealed a larger number of populations, consistent with the presence of short and long monomers and oligomers arising from permutations of the two types of monomers. In addition to disulfide bonds, MUC2 monomers are apparently joined by a "novel," reduction-insensitive bond.The mucosal surface of the gastrointestinal tract is protected by a visco-elastic mucus gel formed by high molecular mass (0.5-25 ϫ 10 6 ) glycoproteins referred to as mucins. The protein backbones of mucins are heavily substituted with O-linked oligosaccharides attached to serine and/or threonine residues, and these amino acids are, together with proline, typically enriched within so-called mucin domains. Several mucin domains may occur in a single mucin subunit and these regions are flanked by less heavily glycosylated segments of the protein core. Large secreted mucins from the respiratory tract, stomach, and endocervix have been shown to be linear oligomers formed by subunits joined via disulfide bonds (1, 2). However, less is known about the macromolecular architecture of intestinal mucins.The mucin genes MUC2, MUC3, MUC4, MUC5B, and MUC6 are expressed in normal human colon (3-7). MUC2 is believed to be the dominating mucus-forming species in this tissue and is, so far, the only "large" mucin of which the cDNA has been fully sequenced (8). The apoprotein contains two mucin domains, which differ in length and are separated by a cysteinecontaining region (Fig. 1A). The longer domain, which is referred to as the variable number tandem repeat (VNTR) 1 region is composed largely of tandemly repeated 23 amino acid peptide units, which vary in number between alleles and are rich in threonine and proline (9, 10). The shorter mucin domain comprises a 347-amino acid-long irregular repeat rich in threonine, serine, and proline. The regions flanking the mucin domains each show a high degree of similarity to the N-and C-terminal cyst...

Pig gastric mucins were isolated from the surface epithelium of the cardiac region, corpus and antrum using density-gradient centrifugation after extraction in 6 M guanidinium chloride. In CsCl/0.5 M guanidinium chloride, mucins solubilized from the cardiac region appeared as a broad unimodal band at 1.52 g/ml whereas those from the corpus and antrum occurred as high- and low-density populations at 1.50 and 1.45 g/ml respectively. High-iron diamine reacted more strongly with the cardiac mucins and the high-density populations from corpus and antrum than with the two low-density ones. In keeping with this, approx. 60% of the oligosaccharides from the former mucins and 20% from the latter contained sulphate. All surface epithelial cells of the cardiac region stained with high-iron diamine, whereas in the corpus only the epithelium in the bottom of the pits reacted, suggesting that the high-density population from this region originates from these cells. Mucins from all regions were composed of subunits, each containing highly glycosylated domains. The mucins from the cardiac region were larger than those from the corpus and antrum, and reduced subunits as well as high-molecular-mass glycopeptides from the cardiac mucins were larger than the corresponding fragments from the other regions. Ion-exchange HPLC showed that reduced subunits from the cardiac mucins and the high-density populations from the corpus and antrum were more ‘acidic’ than reduced subunits from the two low-density ones. All mucins contained a ‘neutral’ fraction, in particular those from the antrum. Pig gastric mucus thus contains a number of distinctly different mucin populations varying in buoyant density, size, ‘acidity’, glycosylation, sulphation and tissue origin.

We found that a whey protein supplement decreased the postprandial chylomicron response compared with casein in persons with abdominal obesity, thereby indicating a beneficial impact on CVD risk. This trial was registered at clinicaltrials.gov as NCT01472666.